NICE Approves Ruxolitinib Cream for Treating Vi...

By HEOR Staff Writer

February 25, 2026

NICE Backs Ruxolitinib Cream Vitiligo Treatment Ruxolitinib cream vitiligo therapy has received a major endorsement from the National Institute for Health and Care Excellence (NICE), w...
Economic Impact of Industry Clinical Trials in Europe
EMA Validation of ENHERTU Breast Cancer Treatment for Post-Neoadjuvant Therapy
European Commission Approves Enhanced Wegovy Obesity Treatment Dose
Genotype ECG Prediction
NICE Endorses Pegzilarginase for Treating Arginase Deficiency
Late-Breaking Data on Bladder Cancer Treatments from KEYNOTE-B15 Trial
AstraZeneca Financial Results: Strong Revenue Growth and Pipeline Expansion i...
KEYTRUDA Ovarian Cancer Treatments: FDA Approves New Regimens for Platinum-Re...
National HealthTech Access: Transforming NHS Adoption and Equity
Datroway Metastatic Breast Cancer: FDA Grants Priority Review for Breakthroug...
FDA Confirms GLP-1 RA Safety Review: No Increased Suicidal Risk
CHMP January 2026 Approvals: Expanding Access to Innovative Therapies